Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1HER2-positive Breast Cancer 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Breast Cancer With Brain Metastasis 1Brain Neoplasms 1

Interventions

Radiotherapy 4aflutinib 3Saline Solution 3Radiosurgery 3pembrolizumab 2Temozolomide 2Receptors, Interleukin-8B 2Pemetrexed 2Memantine 2Magnetic Resonance Spectroscopy 2Indocyanine Green 2Dexmedetomidine 2Cyclophosphamide 2Carboplatin 2Blood Specimen Collection 2Bevacizumab 2vorasidenib 1urinastatin 1trastuzumab deruxtecan 1tovorafenib 1sacituzumab govitecan 1posaconazole 1peginterferon alfa-2b 1osimertinib 1neratinib 1montelukast 1gallium maltolate 1fludarabine 1dalpiciclib 1asciminib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Brain Neoplasms × neratinib × Clear all
NCT06374888 2024-04-19

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
28 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡